Latest Headlines

Latest Headlines

Moody's eyes investor backlash for InVentiv after CRO acquisitions

Moody's Investors Service, a division of the Moody's Corporation, downgraded the ratings outlook for InVentiv from stable to negative.

CRO consolidation continues as inVentiv scoops up PharmaNet

The CRO side of the drug development business has been consolidating at a rapid pace over the last 12 months. And inVentiv Health is helping accelerate that trend with the news that it is snapping up

CRO PharmaNet finds buyer

Just weeks after putting itself up for sale, CRO PharmaNet has agreed to merge with affiliates of private equity group JLL Partners. JLL will pay $5 a share for all outstanding shares of PharmaNet,

CRO PharmaNet may sell business

Princeton, NJ-based CRO PharmaNet Development Group said it's talking with a financial advisor to pursue "strategic alternatives," including the possible sale of the company. PharmaNet makes the